Who
Paul Maier V
Director
Company insider
Files Form 4 as: Director, International Stem Cell; Director, Eton Pharmaceuticals; Director, Ambrx Biopharma; Director, Ambrx Biopharma; Director, FF EAI Robotics Ecosystem; Director, Mabvax Therapeutics Holdings; Director, Apricus Biosciences; Chief Financial Officer, Sequenom.
In numbers
- Trades disclosed
- 380
- Buys
- 5
- Sells
- 39
- Bought
- $79K
- Sold
- $14.1M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 10 Mar 2006
- Last trade
- 16 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 17 Sep 2026 | International Stem Celloption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | International Stem Cell | SEC FORM 4 Sold | $10K32,802 at $0.32 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $189K50,000 at $3.78 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.1M36,387 at $58.64 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $812K13,485 at $60.21 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $7,907128 at $61.77 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $91K12,500 at $7.31 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $189K50,000 at $3.78 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.1M36,387 at $58.64 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $812K13,485 at $60.21 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $7,907128 at $61.77 | filing |
| 28 Aug 2026filed 31 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $91K12,500 at $7.31 | filing |
| 28 Aug 2026filed 28 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $189K50,000 at $3.78 | filing |
| 28 Aug 2026filed 28 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.1M36,387 at $58.64 | filing |
| 28 Aug 2026filed 28 Aug 2026 | ETON Eton PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $812K13,485 at $60.21 | filing |
| 28 Aug 2026filed 28 Aug 2026 | ETON Eton Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
News
Contrasting Eton Pharmaceuticals (NASDAQ:ETON) and Biofrontera (NASDAQ:BFRI)ETON · themarketsdaily.com · 24 Oct 2026Eton (NASDAQ: ETON) secures LIBERVANT license with milestones up to $47.5 millionETON · themarketsdaily.com · 14 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmETON · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Paul Maier V; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.